The incident of the botulinum toxin poisoning of black-faced spoonbills, which occurred in the west-coast marshlands of Taiwan in 2010, triggered OBI Pharma to take an interest in developing Taiwan's native botulinum toxin that gave birth to OBI-858.

OBI Pharma (4174.TWO) Inc., as known as focuses on the oncology of new drugs targeting Globo Series, OBI-858 is the first patented 760kDa formulation in many countries. In addition, due to its non-animal and non-alcohol derived formulation, it receives the Halal Certificate issued by the Taipei Grand Mosque Foundation.

Since the progress of OBI-858's development had reached a stage where it would require more resources for clinical trials, product production, and commercialization, OBIGEN Pharma spun-off from OBI Pharma in December 2020 and proceeded with fundraising and operation independently.